- Display 15 Products per page
Drug Delivery Markets, Vol III – Pulmonary Delivery Systems
Published: March 1, 2007 | Price: $2,495.00 – $4,990.00
The lungs are considered by many to be the best alternative for drugs needing to bypass the gastrointestinal tract. With advancing technology, the practice of utilizing the huge surface area of the lungs to delivery drugs into the blood circulation has been slowly transforming into reality. The pulmonary drug delivery market reached $25.5 billion in 2006 and is expected to experience high steady growth in the next five years. Contributing to growth are new technologies such as dry powder inhalers...
Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Drug Delivery
Published: April 1, 2007 | Price: $2,495.00 – $4,990.00
New biological treatments are being developed at a record pace, but their potential could be compromised by a significant obstacle: the delivery of these drugs into the body. Pharmaceutical delivery is now nearly as important as product. Kalorama's Drug Delivery Markets Series covers these new systems. The fourth volume of this series, Kalorama's Drug Delivery Markets, Vol. IV: Transdermal and Transmucosal Drug Delivery is a complete overview of a delivery mechanism that offers some advantages: low pain, infection risk, fewer...
Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems
Published: September 1, 2009 | Price: $2,995.00 – $5,990.00
With pharmaceutical companies increasingly looking for ways to extend the revenue-earning lifetime of their biggest products, drug delivery has become an important focus of the industry. Kalorama’s Drug Delivery Markets: Implantable / Injectable and Needle-Free Delivery Systems provides detail for business planners on the market for implantable / injectable delivery system markets. Biopharmaceutical products are driving growth of needle-free systems; there will likely be significant increases in revenues in the vaccine arena. This report looks at that trend and reports...
Drug Delivery Markets: Oral Delivery
Published: July 1, 2000 | Price: $995.00 – $5,990.00
Since our last edition of this report in 2007, the oral drug delivery market is the largest segment of the drug delivery market, and there’s no sign that it is slowing down. With pharmaceutical companies increasingly turning to drug delivery to extend the revenue-earning lifetime of their biggest products, and seeking to tap into the growing elderly population that requires products with a level of ease-of-use and cost benefit, it’s no surprise that the oral drug delivery market is a...
Drug Delivery Series I-IV (Oral, Implantable/Injectable, Pulmonary and Transdermal/Transmucosal Systems)
Published: April 1, 2007 | Price: $4,995.00 – $9,990.00
Novel pharmacological and biological approaches to disease are calling for novel systems of delivering therapies. This has focused attention on the market for drug delivery systems and the pharmaceuticals that are sold along with those technologies. Kalorama's Drug Delivery Systems focuses on these technologies. This offer is for the entire 4 volumes of Kalorama's 2nd edition of its Drug Delivery Markets series, covering all major types, including: Oral Delivery Implantable/Injectable Pulmonary Transdermal/Transmucosal While oral delivery remains the most popular and...
Drug Delivery Technology and Applications: A summary of Kalorama’s market research, 2001-2003
Published: November 7, 2003 | Price: $746.00 – $1,492.00
Over the past three years, Kalorama Information's analysts have studied drug delivery markets from several angles. In 2001 and 2002, we published a 5-volume series on drug delivery technology, each volume devoted to a route of administration: Volume I: Oral Drug Delivery Volume II: Injectable and Implantable Drug Delivery Volume III: Pulmonary Drug Delivery Volume IV: Transdermal and Transmucousal Drug Delivery Volume V: Advanced Drug Delivery This series segmented the market by technology and included an innovative analysis that estimated...
Drug Pricing and Reimbursement Strategies: Preparing for the Coming Generic Onslaught
Published: October 1, 2007 | Price: $995.00 – $1,990.00
It can be said that pharmaceutical companies face a 'new era.' in the coming years. Old strategies will not produce the same results. A wave of generic competition is poised to affect most brands. Drug companies have had to cut research budgets, leading to a dearth of new products on the market. This means there is very little margin for error in the pricing decision. Drug pricing is one of the key levers that determine the profitability of a drug...
Drug-Eluting Stents: Markets and Technologies
Published: April 1, 2003 | Price: $1,875.00 – $3,750.00
Each year in the United States, more than 500,000 people with coronary artery disease are treated with percutaneous transluminal coronary angioplasty (PTCA). Unfortunately, restenosis occurs within three to six months in 40% to 50% of PTCA patients due to either thrombosis or abnormal tissue growth. As a result, restenosis constitutes the major limitation to the effectiveness of PTCA. To improve on this condition, medical science created stents in an attempt to keep coronary arteries open. However, one of the early...
Drugs of Abuse Testing Markets: Forecasts to 2018 (Lab-Based, Professional POC, Home, Employment, Criminal Justice Markets)
Published: July 14, 2014 | Price: $995.00 – $1,990.00
Drugs of Abuse is an important growth category in IVD testing with competitive participation by top IVD vendors for market share. Healthcare professionals, employers, criminal justice personnel, and sports use drug tests as part of a comprehensive evaluation of individuals to reach a correct decision regarding the individuals’ actions, behaviors or performances. This report covers trends and markets in drugs of abuse testing. As part of its coverage, the report offers estimates and forecasts for drugs of abuse markets, and...
Early Stage Drug Discovery 2004: Combi-chem & High Throughput Screening Revisited
Published: June 1, 2004 | Price: $2,995.00 – $5,990.00
Ten years ago, high throughput screening (HTS) was being touted as the answer to improving productivity in drug discovery. If screening thousands of compounds a week was good, screening hundreds of thousands would be even better. This led to the boom in Ultra HTS (UHTS), manufacturing-scale systems, and high-speed automation. Today, reality has begun to creep in: HTS and UHTS have not lived up to their hype. R&D productivity is not improving, in fact it may be declining. In the...
Early Toxicology – Markets and Approaches
Published: June 1, 2007 | Price: $1,990.00 – $6,990.00
Toxicity is a crucial parameter that is measured throughout the drug development process. Toxic side-effects are one of the most common reasons drug candidates fail. Toxicity can be a factor of dose, the form in which the drug is administered, and the time of exposure before elimination. Patient responses also differ widely, depending on their age and metabolism and other products in the patient’s system may augment the effect of the drug. Just twenty years ago, toxicology was something that...
Early Toxicology: Markets and Approaches
Published: September 12, 2012 | Price: $3,995.00 – $7,990.00
Early toxicology testing is emerging as one of the mostsignificant areas of drug discovery. Toxicity is no longer something that can be left to the development stage, or just a small part of ADMET. Toxicity determinations are an integral part of all aspects of drug discovery & development. This report, Early Toxicology Markets and Approaches, focuses on markets for early toxicology testing services. The objective of this report is to focus the reader’s attention on the issues and opportunities related...
Effective Competitive Intelligence: A “How-To” Guide for Life Science Companies
Published: November 1, 2008 | Price: $195.00 – $995.00
Often what separates successful marketing from bad is good competitive intelligence. This is true in life sciences as much as other industries. Many companies approach CI in a way that is unplanned, indirect and harmful to their business. But how does one know if they are conducting their company's CI in the best way? If you are trying to determine how to use competitive intelligence better, if you are attempting to judge your efforts compared to companies that have been...
Electrical and Magnetic Neurostimulation: Applications, Technologies, and Market Potential
Published: February 1, 2010 | Price: $2,500.00 – $5,000.00
Stimulation of muscles and nerves by the use of electrical stimulation, notably TENS and EMS, has long been part of pain management. But recent developments, such as implanted technologies and the small size/low cost systems, have created a pathway for increased usage and revenue growth. The growing approval of these applications by government regulators and insurance carriers have helped boost demand. Since Kalorama Information's last look at this market six years ago, several implanted electrode therapeutic systems have recently emerged...
Electrical and Magnetic Neurostimulation: Applications, Technologies, and Market Potential
Published: September 1, 2004 | Price: $3,500.00 – $7,000.00
Neural and muscular stimulation by electronic and magnetic means have evolved into a burgeoning product development and commercial fields. For decades, transcutaneous electronic nerve stimulation (TENS) has been a mainstay in the pain relief arsenal. Through the years, as biocompatibility problems were being solved, electrode and sensor implants developed into a multitude of technologies with healthcare applications. The growing approval of these applications by government regulators and the growing acceptance by insurance carriers have driven the market. These techniques have...